Preimplantation Genetic Testing Market Size, Top Share And Regional Analysis to 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Preimplantation Genetic Testing Market Size Analysis

Global Preimplantation Genetic Testing Market Introduction
By Procedure
1. Introduction
  1. Procedure By Value
2. Preimplantation Genetic Screening (PGS)
  1. By Value
3. Preimplantation Genetic Diagnosis (PGD)
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Reagents and Consumables
  1. By Value
3. Instruments
  1. By Value
4. Software
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing (NGS)
  1. By Value
3. Polymerase Chain Reaction (PCR)
  1. By Value
4. Fluorescent In Situ Hybridisation (FISH)
  1. By Value
5. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Chromosomal Abnormalities
  1. By Value
3. Aneuploidy Screening
  1. By Value
4. X-linked Diseases
  1. By Value
5. Embryo Testing
  1. By Value
6. Human Leukocyte Antigen (HLA) Typing
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Fertility Centres
  1. By Value
4. Diagnostic Centres
  1. By Value
5. Research Centres and Academic Labs
  1. By Value

North America Market Analysis

Introduction
By Procedure
1. Introduction
  1. Procedure By Value
2. Preimplantation Genetic Screening (PGS)
  1. By Value
3. Preimplantation Genetic Diagnosis (PGD)
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Reagents and Consumables
  1. By Value
3. Instruments
  1. By Value
4. Software
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing (NGS)
  1. By Value
3. Polymerase Chain Reaction (PCR)
  1. By Value
4. Fluorescent In Situ Hybridisation (FISH)
  1. By Value
5. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Chromosomal Abnormalities
  1. By Value
3. Aneuploidy Screening
  1. By Value
4. X-linked Diseases
  1. By Value
5. Embryo Testing
  1. By Value
6. Human Leukocyte Antigen (HLA) Typing
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Fertility Centres
  1. By Value
4. Diagnostic Centres
  1. By Value
5. Research Centres and Academic Labs
  1. By Value
U.S.
1. By Procedure
  1. Introduction
    1. Procedure By Value
  2. Preimplantation Genetic Screening (PGS)
    1. By Value
  3. Preimplantation Genetic Diagnosis (PGD)
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Reagents and Consumables
    1. By Value
  3. Instruments
    1. By Value
  4. Software
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing (NGS)
    1. By Value
  3. Polymerase Chain Reaction (PCR)
    1. By Value
  4. Fluorescent In Situ Hybridisation (FISH)
    1. By Value
  5. Others
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Chromosomal Abnormalities
    1. By Value
  3. Aneuploidy Screening
    1. By Value
  4. X-linked Diseases
    1. By Value
  5. Embryo Testing
    1. By Value
  6. Human Leukocyte Antigen (HLA) Typing
    1. By Value
  7. Others
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Fertility Centres
    1. By Value
  4. Diagnostic Centres
    1. By Value
  5. Research Centres and Academic Labs
    1. By Value
Canada

Europe Market Analysis

Introduction
By Procedure
1. Introduction
  1. Procedure By Value
2. Preimplantation Genetic Screening (PGS)
  1. By Value
3. Preimplantation Genetic Diagnosis (PGD)
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Reagents and Consumables
  1. By Value
3. Instruments
  1. By Value
4. Software
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing (NGS)
  1. By Value
3. Polymerase Chain Reaction (PCR)
  1. By Value
4. Fluorescent In Situ Hybridisation (FISH)
  1. By Value
5. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Chromosomal Abnormalities
  1. By Value
3. Aneuploidy Screening
  1. By Value
4. X-linked Diseases
  1. By Value
5. Embryo Testing
  1. By Value
6. Human Leukocyte Antigen (HLA) Typing
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Fertility Centres
  1. By Value
4. Diagnostic Centres
  1. By Value
5. Research Centres and Academic Labs
  1. By Value
U.K.
1. By Procedure
  1. Introduction
    1. Procedure By Value
  2. Preimplantation Genetic Screening (PGS)
    1. By Value
  3. Preimplantation Genetic Diagnosis (PGD)
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Reagents and Consumables
    1. By Value
  3. Instruments
    1. By Value
  4. Software
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing (NGS)
    1. By Value
  3. Polymerase Chain Reaction (PCR)
    1. By Value
  4. Fluorescent In Situ Hybridisation (FISH)
    1. By Value
  5. Others
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Chromosomal Abnormalities
    1. By Value
  3. Aneuploidy Screening
    1. By Value
  4. X-linked Diseases
    1. By Value
  5. Embryo Testing
    1. By Value
  6. Human Leukocyte Antigen (HLA) Typing
    1. By Value
  7. Others
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Fertility Centres
    1. By Value
  4. Diagnostic Centres
    1. By Value
  5. Research Centres and Academic Labs
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Procedure
1. Introduction
  1. Procedure By Value
2. Preimplantation Genetic Screening (PGS)
  1. By Value
3. Preimplantation Genetic Diagnosis (PGD)
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Reagents and Consumables
  1. By Value
3. Instruments
  1. By Value
4. Software
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing (NGS)
  1. By Value
3. Polymerase Chain Reaction (PCR)
  1. By Value
4. Fluorescent In Situ Hybridisation (FISH)
  1. By Value
5. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Chromosomal Abnormalities
  1. By Value
3. Aneuploidy Screening
  1. By Value
4. X-linked Diseases
  1. By Value
5. Embryo Testing
  1. By Value
6. Human Leukocyte Antigen (HLA) Typing
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Fertility Centres
  1. By Value
4. Diagnostic Centres
  1. By Value
5. Research Centres and Academic Labs
  1. By Value
China
1. By Procedure
  1. Introduction
    1. Procedure By Value
  2. Preimplantation Genetic Screening (PGS)
    1. By Value
  3. Preimplantation Genetic Diagnosis (PGD)
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Reagents and Consumables
    1. By Value
  3. Instruments
    1. By Value
  4. Software
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing (NGS)
    1. By Value
  3. Polymerase Chain Reaction (PCR)
    1. By Value
  4. Fluorescent In Situ Hybridisation (FISH)
    1. By Value
  5. Others
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Chromosomal Abnormalities
    1. By Value
  3. Aneuploidy Screening
    1. By Value
  4. X-linked Diseases
    1. By Value
  5. Embryo Testing
    1. By Value
  6. Human Leukocyte Antigen (HLA) Typing
    1. By Value
  7. Others
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Fertility Centres
    1. By Value
  4. Diagnostic Centres
    1. By Value
  5. Research Centres and Academic Labs
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Procedure
1. Introduction
  1. Procedure By Value
2. Preimplantation Genetic Screening (PGS)
  1. By Value
3. Preimplantation Genetic Diagnosis (PGD)
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Reagents and Consumables
  1. By Value
3. Instruments
  1. By Value
4. Software
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing (NGS)
  1. By Value
3. Polymerase Chain Reaction (PCR)
  1. By Value
4. Fluorescent In Situ Hybridisation (FISH)
  1. By Value
5. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Chromosomal Abnormalities
  1. By Value
3. Aneuploidy Screening
  1. By Value
4. X-linked Diseases
  1. By Value
5. Embryo Testing
  1. By Value
6. Human Leukocyte Antigen (HLA) Typing
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Fertility Centres
  1. By Value
4. Diagnostic Centres
  1. By Value
5. Research Centres and Academic Labs
  1. By Value
UAE
1. By Procedure
  1. Introduction
    1. Procedure By Value
  2. Preimplantation Genetic Screening (PGS)
    1. By Value
  3. Preimplantation Genetic Diagnosis (PGD)
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Reagents and Consumables
    1. By Value
  3. Instruments
    1. By Value
  4. Software
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing (NGS)
    1. By Value
  3. Polymerase Chain Reaction (PCR)
    1. By Value
  4. Fluorescent In Situ Hybridisation (FISH)
    1. By Value
  5. Others
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Chromosomal Abnormalities
    1. By Value
  3. Aneuploidy Screening
    1. By Value
  4. X-linked Diseases
    1. By Value
  5. Embryo Testing
    1. By Value
  6. Human Leukocyte Antigen (HLA) Typing
    1. By Value
  7. Others
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Fertility Centres
    1. By Value
  4. Diagnostic Centres
    1. By Value
  5. Research Centres and Academic Labs
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Procedure
1. Introduction
  1. Procedure By Value
2. Preimplantation Genetic Screening (PGS)
  1. By Value
3. Preimplantation Genetic Diagnosis (PGD)
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Reagents and Consumables
  1. By Value
3. Instruments
  1. By Value
4. Software
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing (NGS)
  1. By Value
3. Polymerase Chain Reaction (PCR)
  1. By Value
4. Fluorescent In Situ Hybridisation (FISH)
  1. By Value
5. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Chromosomal Abnormalities
  1. By Value
3. Aneuploidy Screening
  1. By Value
4. X-linked Diseases
  1. By Value
5. Embryo Testing
  1. By Value
6. Human Leukocyte Antigen (HLA) Typing
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Fertility Centres
  1. By Value
4. Diagnostic Centres
  1. By Value
5. Research Centres and Academic Labs
  1. By Value
Brazil
1. By Procedure
  1. Introduction
    1. Procedure By Value
  2. Preimplantation Genetic Screening (PGS)
    1. By Value
  3. Preimplantation Genetic Diagnosis (PGD)
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Reagents and Consumables
    1. By Value
  3. Instruments
    1. By Value
  4. Software
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing (NGS)
    1. By Value
  3. Polymerase Chain Reaction (PCR)
    1. By Value
  4. Fluorescent In Situ Hybridisation (FISH)
    1. By Value
  5. Others
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Chromosomal Abnormalities
    1. By Value
  3. Aneuploidy Screening
    1. By Value
  4. X-linked Diseases
    1. By Value
  5. Embryo Testing
    1. By Value
  6. Human Leukocyte Antigen (HLA) Typing
    1. By Value
  7. Others
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Fertility Centres
    1. By Value
  4. Diagnostic Centres
    1. By Value
  5. Research Centres and Academic Labs
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Preimplantation Genetic Testing Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Oxford Gene Technology
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Thermo Fisher Scientific Inc.
SciGene Corporation
Agilent Technologies Inc.
PerkinElmer Inc.
Coopersurgical Inc.
Abbott Laboratories
Illumina Inc.
Natera Inc
Yikon Genomics

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment